President Donald Trump announced agreements with nine additional pharmaceutical companies on Monday as part of the administration's effort to lower prescription drug costs through the Most Favored Nation (MFN) drug pricing initiative. This brings the total number of participating drugmakers to 26 and covers approximately 89 percent of the branded pharmaceutical market.
The agreements, which target around 89 percent of the branded pharmaceutical market, include products for treating conditions such as hemophilia, Parkinson's disease, glaucoma, macular degeneration, and certain cancers. The White House stated that these deals could generate billions of dollars in savings for Medicaid and patients.
Brief written by urgent.news from Newsweek's own syndicated text.
Machine-written — may contain errors; check the original before relying on it.
Spatial transcriptomics is a powerful tool for creating a detailed map of not just how genes are expressed in a piece of tissue, but also where genetic activity takes place in different cells and…
